Untapped Potential in Women’s Health: An Analysis of Gender Imbalance in Life Science Investment
An exploration on how closing the gender gap in healthcare could improve women’s health and improve the global economy.
From a demographic and economic standpoint, investing in women’s health research and development should present an obvious opportunity for the pharmaceutical industry. Females make up more than 50% of the US population, enjoy a longer lifespan than their male counterparts and are more likely to be insured. Yet, women’s health has been underfunded and under-studied in the US.
Closing the gender gap in healthcare is a pressing goal for policymakers and leaders within the healthcare system as a whole. Improving health equity for women is both a focus of directives from the White House and an animating topic within the pharmaceutical industry.
Download the white paper below for an overview and exploration of an analysis on how closing the gender health gap could reduce the time women spend in poor health by almost two-thirds and add up to $1 trillion to the global economy annually by 2040.
Related Content
Looking for exclusive insight?
